TP53 and B-cell non-Hodgkin lymphoma: They found that the treatment induced cell death in the cancer cells and resulted in prolonged survival in a mouse model, indicating that p53 gene therapy using CRISPR/Cas9 may be an effective treatment for B-cell lymphoma [665].